Juno Therapeutics (JUNO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
2 shs
Average Volume
5.48 million shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
JUNO stock logo

About Juno Therapeutics Stock (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

JUNO Stock News Headlines

Out of the lab and into the factory
EFTR eFFECTOR Therapeutics, Inc.
What we know about Jeff Bezos’ net worth
How Zelda Williams Found Humor in Trauma
See More Headlines
Receive JUNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Howard H. Pien (Age 59)
    Independent Chairman of the Board
  • Hans Edgar Bishop (Age 53)
    President, Chief Executive Officer, Director
  • Sunil Agarwal M.D. (Age 47)
    President of Research & Development
  • Steven D. Harr M.D. (Age 46)
    Chief Financial Officer, Head of Corporate Development
  • Hyam I. Levitsky M.D (Age 54)
    Executive vice president - Research, chief scientific officer
  • Robert W. Azelby (Age 49)
    Executive Vice President, Chief Commercial Officer
  • Ann Lee Ph.D.
    Executive Vice President - Technical Operations
  • Patrick Y. Yang (Age 69)
    Executive Vice President
  • Cynthia Elkins
    Chief Information Officer
  • Bernard J. Cassidy (Age 62)
    General Counsel, Secretary

JUNO Stock Analysis - Frequently Asked Questions

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) released its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. The company's revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.57) earnings per share.

What other stocks do shareholders of Juno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).

When did Juno Therapeutics IPO?

Juno Therapeutics (JUNO) raised $153 million in an initial public offering on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

This page (NASDAQ:JUNO) was last updated on 5/18/2024 by Staff

From Our Partners